These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24419062)

  • 1. Increases in duration of first highly active antiretroviral therapy over time (1996-2009) and associated factors in the Multicenter AIDS Cohort Study.
    Slama L; Li X; Brown T; Jacobson LP; Pialoux G; Macatangay B; Bolan RK; Phair J; Palella FJ;
    J Acquir Immune Defic Syndr; 2014 Jan; 65(1):57-64. PubMed ID: 24419062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
    Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
    HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
    Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton SE; van Lunzen J; Katzenstein TL; Antunes F; Lundgren JD; Clotet B
    Arch Intern Med; 2000 Apr; 160(8):1123-32. PubMed ID: 10789605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study.
    Yamashita TE; Phair JP; Muñoz A; Margolick JB; Detels R; O'Brien SJ; Mellors JW; Wolinsky SM; Jacobson LP
    AIDS; 2001 Apr; 15(6):735-46. PubMed ID: 11371688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma.
    Hoffmann C; Wolf E; Fätkenheuer G; Buhk T; Stoehr A; Plettenberg A; Stellbrink HJ; Jaeger H; Siebert U; Horst HA
    AIDS; 2003 Jul; 17(10):1521-9. PubMed ID: 12824790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden.
    Hill S; Kavookjian J; Qian J; Chung A; Vandewaa J
    AIDS Care; 2014; 26(5):595-601. PubMed ID: 24111921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda.
    Abaasa AM; Todd J; Ekoru K; Kalyango JN; Levin J; Odeke E; Karamagi CA
    BMC Health Serv Res; 2008 Nov; 8():241. PubMed ID: 19021908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.
    Nolan S; Milloy MJ; Zhang R; Kerr T; Hogg RS; Montaner JS; Wood E
    AIDS Care; 2011 Aug; 23(8):980-7. PubMed ID: 21480010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study.
    Kouanda S; Meda IB; Nikiema L; Tiendrebeogo S; Doulougou B; Kaboré I; Sanou MJ; Greenwell F; Soudré R; Sondo B
    AIDS Care; 2012; 24(4):478-90. PubMed ID: 22148973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrush and fever as markers of immune competence in the era of highly active antiretroviral therapy.
    Skolasky RL; Phair J; Detels R; Riddler S; Margolick J; Jacobson LP
    AIDS Res Hum Retroviruses; 2001 Sep; 17(14):1311-6. PubMed ID: 11602040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
    Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
    Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study.
    Kirstein LM; Greenblatt RM; Anastos K; Levine A; French AL; Minkoff H; Silver S; Gange SJ;
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):495-503. PubMed ID: 11981366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
    Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
    Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
    Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
    Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.
    Li X; Margolick JB; Jamieson BD; Rinaldo CR; Phair JP; Jacobson LP
    J Acquir Immune Defic Syndr; 2011 Aug; 57(5):421-8. PubMed ID: 21602699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment initiation factors and cognitive outcome in youth with perinatally acquired HIV infection.
    Lazarus JR; Rutstein RM; Lowenthal ED
    HIV Med; 2015 Jul; 16(6):355-61. PubMed ID: 25604610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.